BRAF and ganglioglioma: A safety and pilot efficacy clinical trial of vemurafenib as a single agent against BRAF V600E mutant recurrent or refractory low-grade ganglioglioma in children is ongoing (ClinicalTrials.gov Identifier: NCT01748149).